Bone Marrow Research [32] N. Leung, A. Dispenzieri, F. C. Fervenza et al., “Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis,” American Journal of Kidney Diseases, vol. 46, no. 2, pp. 270–277, 2005. [33] M. Skinner, V. Sanchorawala, D. C. Seldin et al., “High- dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study,” Annals of Internal Medicine, vol. 140, no. 2, pp. 85–93, 2004. [34] S. Madan, S. K. Kumar, A. Dispenzieri et al., “High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement,” Blood, vol. 46, no. 5, pp. 1117–1122. [35] I. I. Van Gameren, M. H. Van Rijswijk, J. Bijzet, E. Vellenga, and B. P. Hazenberg, “Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain,” Haematologica, vol. 94, no. 8, pp. 1094–1100, 2009. [36] A. Dispenzieri, M. Q. Lacy, R. A. Kyle et al., “Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival,” Journal of Clinical Oncology, vol. 19, no. 14, pp. 3350–3356, 2001. [37] A. Dispenzieri, R. A. Kyle, M. Q. Lacy et al., “Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study,” Blood, vol. 103, no. 10, pp. 3960–3963, 2004. [38] D. C. Seldin, J. J. Anderson, V. Sanchorawala et al., “Improve- ment in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation,” Blood, vol. 104, no. 6, pp. 1888–1893, 2004. [39] A. Jaccard, P. Moreau, V. Leblond et al., “High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis,” New England Journal of Medicine, vol. 357, no. 11, pp. 1083– 1093, 2007. [40] S. Kumar, A. Dispenzieri, and M. A. Gertz, “High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis,” New England Journal of Medicine, vol. 358, no. 1, p. 91, 2008. [41] J. Mehta, “High-dose melphalan versus melphalan plus dex- amethasone for AL amyloidosis,” New England Journal of Medicine, vol. 358, no. 1, p. 91, 2008. [42] R. L. Comenzo, R. M. Steingart, and A. D. Cohen, “High- dose melphalan versus melphalan plus dexamethasone for AL amyloidosis,” New England Journal of Medicine, vol. 358, no. 1, p. 92, 2008. [43] R. Mhaskar, A. Kumar, M. Behera, M. A. Kharfan-Dabaja, and B. Djulbegovic, “Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review,” Biology of Blood and Marrow Transplantation, vol. 15, no. 8, pp. 893–902, 2009. [44] E. Kastritis, A. D. Wechalekar, M. A. Dimopoulos et al., “Bortezomib with or without dexamethasone in primary sys- temic (light chain) amyloidosis,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1031–1037, 2010. [45] C. Gasparetto, V. Sanchorawala, R. M. Snyder et al., “Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis,” Journal of Clinical Oncology, vol. 28, abstract 8024, 2010. [46] V. Jimenez-Zepeda, C. B. Reeder, J. R. Mikhael et al., “Cyclophosphamide, bortezomib and dexamethasone (CyBORD) induces rapid and complete responses in patients with amyloidosis not eligible for peripheral blood stem cell transplant,” Blood, vol. 114, abstract 1857, 2010. 5 [47] M. W. Brunvand and M. Bitter, “Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and rever- sal of tissue damage with improved suitability for transplant,” Haematologica, vol. 95, no. 3, pp. 519–521, 2010. [48] Mayo Consensus on AL Amyloidosis: Diagnosis and Treatment, 2011, http://www.msmart.org/msmart mar09 002 .htm.